← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Battelle Memorial Institu
Columbus, OH
$67,383,603
Total funding
3
Grants
Funding over time
peak $23.9M · FY2016–24$25M$18.8M$12.5M$6.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$67,383,603 · 3
By mechanism
N01$67,383,603 · 3
Investigators at Battelle Memorial Institu
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Conduct of studies to evaluate the toxic and carcinogenic potential of naturally occurring asbestos and related mineral fibers in laboratory animals$5,393,328
N01 · FY2021 · ES
Conduct of studies to evaluate the toxic and carcinogenic potential of naturally occurring asbestos and related mineral fibers in laboratory animals$5,330,513
N01 · FY2023 · ES
Conduct of studies to evaluate the toxic potential of C9-alkylbenzenes in laboratory animals$3,984,892
N01 · FY2023 · ES
Conduct of studies to evaluate the toxic potential of C9-alkylbenzenes in laboratory animals$3,931,148
N01 · FY2021 · ES
Conduct of studies to evaluate the toxic and carcinogenic potential of naturally occurring asbestos and related mineral fibers in laboratory animals$3,709,608
N01 · FY2022 · ES
Conduct of studies to evaluate the subchronic and developmental neurotoxicity of isopropylated phenol phosphate (IPP) in rats (after perinatal exposure)$3,344,706
N01 · FY2021 · ES
Conduct of studies to evaluate the toxic potential of C9-alkylbenzenes in laboratory animals$2,636,818
N01 · FY2022 · ES
Support for the Conduct of Studies to Evaluate the Impact of Genetic Background and Potential Treatments of SARS-CoV-2 Induced Pneumonia$2,516,993
N01 · FY2021 · ES
Conduct of Studies to Evaluate the Cardiovascular Toxicity of an HIV Tricombo Therapy (ABC/DTG/3TC) ing Sprague Dawley Rats (F0 Dosed by Oral Gavage; F1 Exposed Perinatally)$2,164,226
N01 · FY2023 · ES
Conduct of studies to evaluate the subchronic and developmental neurotoxicity of isopropylated phenol phosphate (IPP) and triphenyl phosphate (TPHP)in rats (after perinatal exposure)$1,985,021
N01 · FY2023 · ES
Support of the Research Effort to Evaluate the Cardiotoxic Potential of Multiple Test Agents in Rats$1,932,991
N01 · FY2023 · ES
Conduct of studies to evaluate the subchronic and developmental neurotoxicity of triphenyl phosphate (TPHP) in rats (after perinatal exposure)$1,912,683
N01 · FY2022 · ES
Evaluation and use of 2D and 3D HepaRG cells to screen for chemical toxicity$1,745,926
N01 · FY2023 · ES
Establish and Characterize an Air Liquid Interface In Vitro Exposure System$1,490,016
N01 · FY2023 · ES
Conduct of Studies to Evaluate the Cardiovascular Toxicity of an HIV Tricombo Therapy (ABC/DTG/3TC) ing Sprague Dawley Rats (F0 Dosed by Oral Gavage; F1 Exposed Perinatally)$1,449,000
N01 · FY2021 · ES
Evaluation of multiple test agents for functional cardiovascular changes in rats$1,423,206
N01 · FY2023 · ES
Establish and Characterize an Air Liquid Interface In Vitro Exposure System$1,397,365
N01 · FY2021 · ES
Conduct of studies to evaluate the subchronic and developmental neurotoxicity of isopropylated phenol phosphate (IPP) in rats (after perinatal exposure)$1,312,001
N01 · FY2022 · ES
Evaluation of Physiological Monitoring in Tocivology using 2-Ethyltoluene as a case study$1,310,781
N01 · FY2024 · ES
Establish and Characterize an Air Liquid Interface In Vitro Exposure System$1,244,142
N01 · FY2022 · ES